Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cerecor Inc (CERC)

Cerecor Inc (CERC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 281,306
  • Shares Outstanding, K 96,009
  • Annual Sales, $ 6,700 K
  • Annual Income, $ -63,500 K
  • 60-Month Beta 1.44
  • Price/Sales 42.71
  • Price/Cash Flow N/A
  • Price/Book 13.03
Trade CERC with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.66
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/05/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.19
  • Number of Estimates 2
  • High Estimate -0.18
  • Low Estimate -0.19
  • Prior Year -0.16
  • Growth Rate Est. (year over year) -18.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.51 +16.73%
on 07/27/21
3.10 -5.48%
on 08/10/21
+0.08 (+2.81%)
since 07/23/21
3-Month
2.51 +16.73%
on 07/27/21
3.70 -20.81%
on 06/18/21
+0.34 (+13.13%)
since 05/25/21
52-Week
1.98 +47.98%
on 11/02/20
4.50 -34.89%
on 02/22/21
+0.31 (+11.83%)
since 08/25/20

Most Recent Stories

More News
Avalo Therapeutics, Inc. Announces Corporate Name Change from Cerecor Inc.

WAYNE, Pa. and ROCKVILLE, Md., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes...

CERC : 2.93 (-1.68%)
AVTX : 10.87 (+0.74%)
Cerecor Reports Second Quarter 2021 Financial Results and Provides Business Updates

ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization...

CERC : 2.93 (-1.68%)
Cerecor Announces Drawdown of $10 Million Tranche under its Debt Financing Agreement with Horizon Technology Finance

Achieved performance milestone with positive initial results from its Phase 1b trial of CERC-002 in moderate-to- severe Crohn’s Disease who had previously failed three or more lines of biologics therapies,...

CERC : 2.93 (-1.68%)
HRZN : 11.55 (-0.17%)
Cerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn's Disease Patients

ROCKVILLE, Md. and CHESTERBROOK, Pa., July 26, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization...

CERC : 2.93 (-1.68%)
Cerecor Licenses Immune Checkpoint Program from Sanford Burnham Prebys Further Expanding Pipeline of Immunology and Immuno-oncology Targets

Cerecor completes divestiture of non-core neurology pipeline assets as it increases its focus on immunology, immuno-oncology, and rare genetic disorders

CERC : 2.93 (-1.68%)
Cerecor Enters Into $35 Million Debt Financing Agreement With Horizon Technology Finance

ROCKVILLE, Md. and CHESTERBROOK, Pa., June 07, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization...

CERC : 2.93 (-1.68%)
HRZN : 11.55 (-0.17%)
Cerecor to Participate in Upcoming Investor Conferences

ROCKVILLE, Md. and CHESTERBROOK, Pa., May 17, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of...

CERC : 2.93 (-1.68%)
Cerecor Reports First Quarter 2021 Financial Results and Provides Business Updates

ROCKVILLE, Md. and CHESTERBROOK, Pa., May 13, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of...

CERC : 2.93 (-1.68%)
FDA Grants Fast Track Designation to CERC-002 for Treatment of Hospitalized Patients with COVID-19

ROCKVILLE, Md. and CHESTERBROOK, Pa., May 11, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments...

CERC : 2.93 (-1.68%)
Cerecor Doses First Patient in a Phase 1b Proof-of-Concept Clinical Trial of CERC-007 for the Treatment of Adult Onset Still’s Disease

ROCKVILLE, Md. and CHESTERBROOK, Pa., May 05, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments...

CERC : 2.93 (-1.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Cerecor, Inc. is a biopharmaceutical company which focuses on the development of drugs for the treatment of patients with neurological and psychiatric disorders. The company's portfolio of clinical and preclinical candidates consists of CERC-301, CERC-501 and CERC-406. CERC-301; adjunctive antidepressant...

See More

Key Turning Points

3rd Resistance Point 3.05
2nd Resistance Point 3.02
1st Resistance Point 2.97
Last Price 2.93
1st Support Level 2.89
2nd Support Level 2.86
3rd Support Level 2.81

See More

52-Week High 4.50
Fibonacci 61.8% 3.54
Fibonacci 50% 3.24
Fibonacci 38.2% 2.94
Last Price 2.93
52-Week Low 1.98

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar